Literature DB >> 8695347

Alternatively spliced variants of the cell adhesion molecule CD44 and tumour progression in colorectal cancer.

D C Gotley1, J Fawcett, M D Walsh, J A Reeder, D L Simmons, T M Antalis.   

Abstract

Increased expression of alternatively spliced variants of the CD44 family of cell adhesion molecules has been associated with tumour metastasis. In the present study, expression of alternatively spliced variants of CD44 and their cellular distribution have been investigated in human colonic tumours and in the corresponding normal mucosa, in addition to benign adenomatous polyps. The expression of CD44 alternatively spliced variants has been correlated with tumour progression according to Dukes' histological stage. CD44 variant expression was determined by immunohistochemisty using monoclonal antibodies directed against specific CD44 variant domains together with RT-PCR analysis of CD44 variant mRNA expression in the same tissue specimens. We demonstrate that as well as being expressed in colonic tumour cells, the full range of CD44 variants, CD44v2-v10, are widely expressed in normal colonic crypt epithelium, predominantly in the crypt base. CD44v6, the epitope which is most commonly associated with tumour progression and metastasis, was not only expressed by many benign colonic tumours, but was expressed as frequently in normal basal crypt epithelium as in malignant colonic tumour cells, and surprisingly, was even absent from some metastatic colorectal tumours. Expression of none of the CD44 variant epitopes was found to be positively correlated with tumour progression or with colorectal tumour metastasis to the liver, results which are inconsistent with a role for CD44 variants as indicators of colonic cancer progression.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8695347      PMCID: PMC2074640          DOI: 10.1038/bjc.1996.364

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  33 in total

1.  The two major CD44 proteins expressed on a metastatic rat tumor cell line are derived from different splice variants: each one individually suffices to confer metastatic behavior.

Authors:  W Rudy; M Hofmann; R Schwartz-Albiez; M Zöller; K H Heider; H Ponta; P Herrlich
Journal:  Cancer Res       Date:  1993-03-15       Impact factor: 12.701

2.  Control of plasminogen-activator inhibitor type 2 gene expression in the differentiation of monocytic cells.

Authors:  T M Antalis; J L Dickinson
Journal:  Eur J Biochem       Date:  1992-04-01

3.  CD44 splice variants confer metastatic behavior in rats: homologous sequences are expressed in human tumor cell lines.

Authors:  M Hofmann; W Rudy; M Zöller; C Tölg; H Ponta; P Herrlich; U Günthert
Journal:  Cancer Res       Date:  1991-10-01       Impact factor: 12.701

4.  Significance of CD44 gene products for cancer diagnosis and disease evaluation.

Authors:  Y Matsumura; D Tarin
Journal:  Lancet       Date:  1992-10-31       Impact factor: 79.321

5.  A link between ras and metastatic behavior of tumor cells: ras induces CD44 promoter activity and leads to low-level expression of metastasis-specific variants of CD44 in CREF cells.

Authors:  M Hofmann; W Rudy; U Günthert; S G Zimmer; V Zawadzki; M Zöller; R B Lichtner; P Herrlich; H Ponta
Journal:  Cancer Res       Date:  1993-04-01       Impact factor: 12.701

6.  Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons.

Authors:  G R Screaton; M V Bell; D G Jackson; F B Cornelis; U Gerth; J I Bell
Journal:  Proc Natl Acad Sci U S A       Date:  1992-12-15       Impact factor: 11.205

7.  Prevention of tumor metastasis formation by anti-variant CD44.

Authors:  S Seiter; R Arch; S Reber; D Komitowski; M Hofmann; H Ponta; P Herrlich; S Matzku; M Zöller
Journal:  J Exp Med       Date:  1993-02-01       Impact factor: 14.307

8.  Activated human lymphocytes and aggressive non-Hodgkin's lymphomas express a homologue of the rat metastasis-associated variant of CD44.

Authors:  G Koopman; K H Heider; E Horst; G R Adolf; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Exp Med       Date:  1993-04-01       Impact factor: 14.307

9.  A human homologue of the rat metastasis-associated variant of CD44 is expressed in colorectal carcinomas and adenomatous polyps.

Authors:  K H Heider; M Hofmann; E Hors; F van den Berg; H Ponta; P Herrlich; S T Pals
Journal:  J Cell Biol       Date:  1993-01       Impact factor: 10.539

10.  Distinct effects of two CD44 isoforms on tumor growth in vivo.

Authors:  M S Sy; Y J Guo; I Stamenkovic
Journal:  J Exp Med       Date:  1991-10-01       Impact factor: 14.307

View more
  30 in total

1.  CD44 variant exons in leukemia and lymphoma.

Authors:  Elif Akisik; Sevil Bavbek; Nejat Dalay
Journal:  Pathol Oncol Res       Date:  2002       Impact factor: 3.201

2.  Significance of immunohistochemical over-expression of CD44v6 as an indicator of malignant potential in esophageal squamous cell carcinoma.

Authors:  T Nozoe; S Kohnoe; T Ezaki; A Kabashima; Y Maehara
Journal:  J Cancer Res Clin Oncol       Date:  2004-02-11       Impact factor: 4.553

3.  The beta-catenin/TCF4 pathway modifies alternative splicing through modulation of SRp20 expression.

Authors:  Vânia Gonçalves; Paulo Matos; Peter Jordan
Journal:  RNA       Date:  2008-10-24       Impact factor: 4.942

Review 4.  Forms and functions of CD44.

Authors:  G Borland; J A Ross; K Guy
Journal:  Immunology       Date:  1998-02       Impact factor: 7.397

5.  Poor diagnostic value of colonic CD44v6 expression and serum concentrations of its soluble form in the differentiation of ulcerative colitis from Crohn's disease.

Authors:  W Reinisch; K H Heider; G Oberhuber; C Dejaco; M Müllner; G R Adolf; C Gasché
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

6.  Expression of invasion markers CD44v6/v3, NM23 and MMP2 in laryngeal and hypopharyngeal carcinoma.

Authors:  G Répássy; C Forster-Horváth; A Juhász; R Adány; A Tamássy; J Tímár
Journal:  Pathol Oncol Res       Date:  1998       Impact factor: 3.201

7.  Cancer stem cell-associated miRNAs serve as prognostic biomarkers in colorectal cancer.

Authors:  Shusuke Toden; Shigeyasu Kunitoshi; Jacob Cardenas; Jinghua Gu; Elizabeth Hutchins; Kendall Van Keuren-Jensen; Hiroyuki Uetake; Yuji Toiyama; Ajay Goel
Journal:  JCI Insight       Date:  2019-03-21

8.  New-generation taxoid SB-T-1214 inhibits stem cell-related gene expression in 3D cancer spheroids induced by purified colon tumor-initiating cells.

Authors:  Galina I Botchkina; Edison S Zuniga; Manisha Das; Yuan Wang; Hichao Wang; Shu Zhu; Anne G Savitt; Rebecca A Rowehl; Yan Leyfman; Jingfang Ju; Kenneth Shroyer; Iwao Ojima
Journal:  Mol Cancer       Date:  2010-07-14       Impact factor: 27.401

9.  Comparison of cyclooxygenase-2 and CD44 mRNA expression in colorectal cancer and its relevance for prognosis.

Authors:  Jung Wook Huh; Hyeong Rok Kim; Jae Hyuk Lee; Young Jin Kim
Journal:  Virchows Arch       Date:  2009-03-10       Impact factor: 4.064

10.  Expression of proliferating cell nuclear antigen and CD44 variant exon 6 in primary tumors and corresponding lymph node metastases of colorectal carcinoma with Dukes' stage C or D.

Authors:  Ji-Cheng Zhang; Zuo-Ren Wang; Yan-Juan Cheng; Ding-Zhong Yang; Jing-Sen Shi; Ai-Lin Liang; Ning-Na Liu; Xiao-Min Wang
Journal:  World J Gastroenterol       Date:  2003-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.